Androgen Function in the Pathophysiology and Treatment of Male Huntington's Disease Patients

被引:7
|
作者
Ransome, M. I. [1 ]
机构
[1] Univ Melbourne, Florey Neurosci Inst, Melbourne Brain Ctr, Parkville, Vic 3010, Australia
基金
英国医学研究理事会;
关键词
Huntington's disease; androgen; androgen receptor; hypogonadism; testosterone replacement therapy; gonadotrophic axis; GROWTH-FACTOR-I; RECEPTOR POLYMORPHISM; TESTOSTERONE THERAPY; DEPRESSIVE SYMPTOMS; DEPRIVATION THERAPY; PLASMA TESTOSTERONE; PROSTATE-CANCER; MOUSE MODEL; LATE-ONSET; BRAIN;
D O I
10.1111/j.1365-2826.2012.02347.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Low concentrations of circulating testosterone have been associated with dementia manifesting with advancing age and in neurodegenerative conditions. Huntingtons disease (HD) is a dominantly inherited neurodegenerative disease with an invariably fatal outcome. Severe motor symptoms, psychosis and dementia are symptomatic hallmarks of the progression of HD that result from the dysfunction and death of neocortical and basal ganglia neurones. Treatments are directed toward manifest symptoms, although they are largely ineffectual in slowing or preventing disease progression. Emerging data have identified hypothamic pathologies in HD that result in endocrine disturbances. Clinically defined primary or secondary hypogonadism elicit low circulating testosterone concentrations and have been linked to the development of Alzheimers disease in men. Examining similar neuroendocrine dysfunction in HD including the nature of manifest hypogonadism in male patients could allow an elucidation of the complex pathophysiology of HD and provide an impetus for hitherto untested testosterone replacement therapy.
引用
收藏
页码:1275 / 1283
页数:9
相关论文
共 50 条
  • [1] Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease
    Wiprich, Melissa Talita
    Bonan, Carla Denise
    FRONTIERS IN NEUROSCIENCE, 2021, 15
  • [2] Male sexual function in presymptomatic gene carriers and patients with Huntington's disease
    Kolenc, Matej
    Kobal, Jan
    Podnar, Simon
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 359 (1-2) : 312 - 317
  • [3] The pathophysiology and pharmacological treatment of Huntington disease
    Pidgeon, Connie
    Rickards, Hugh
    BEHAVIOURAL NEUROLOGY, 2013, 26 (04) : 245 - 253
  • [4] Pathophysiology of Huntington's disease: An update
    Roze, E.
    Betuing, S.
    Deyts, C.
    Vidailhet, M.
    Caboche, J.
    REVUE NEUROLOGIQUE, 2008, 164 (12) : 977 - 994
  • [5] Pulmonary function in patients with Huntington's Disease
    Reyes, Alvaro
    Cruickshank, Travis
    Ziman, Mel
    Nosaka, Kazunori
    BMC PULMONARY MEDICINE, 2014, 14
  • [6] Pulmonary function in patients with Huntington’s Disease
    Alvaro Reyes
    Travis Cruickshank
    Mel Ziman
    Kazunori Nosaka
    BMC Pulmonary Medicine, 14
  • [7] Astrocytic contributions to Huntington's disease pathophysiology
    Khakh, Baljit S.
    Goldman, Steven A.
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 2023, 1522 (01) : 42 - 59
  • [8] Pathophysiology of chorea and bradykinesia in Huntington's disease
    Berardelli, A
    Noth, J
    Thompson, PD
    Bollen, ELEM
    Curra, A
    Deuschl, G
    van Dijk, JG
    Töpper, R
    Schwarz, M
    Roos, RAC
    MOVEMENT DISORDERS, 1999, 14 (03) : 398 - 403
  • [9] PATHOPHYSIOLOGY OF HUNTINGTON'S DISEASE: TIME-DEPENDENT ALTERATIONS IN SYNAPTIC AND RECEPTOR FUNCTION
    Raymond, L. A.
    Andre, V. M.
    Cepeda, C.
    Gladding, C. M.
    Milnerwood, A. J.
    Levine, M. S.
    NEUROSCIENCE, 2011, 198 : 252 - 273
  • [10] Androgen deficiency in the aging male: Pathophysiology, diagnosis, and treatment alternatives
    Flynn V.
    Hellstrom W.J.G.
    Current Urology Reports, 2001, 2 (6) : 473 - 479